Amneal Pharmaceuticals (NASDAQ:AMRX) Raised to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Amneal Pharmaceuticals (NASDAQ:AMRX) from a buy rating to a strong-buy rating in a research report released on Monday morning.

AMRX has been the topic of several other research reports. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price on the stock in a research note on Friday, September 6th. Piper Sandler lifted their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday. Truist Financial lifted their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd. Finally, Barclays lifted their target price on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Trading Down 0.3 %

NASDAQ AMRX opened at $9.00 on Monday. Amneal Pharmaceuticals has a 1 year low of $4.16 and a 1 year high of $9.48. The stock’s 50-day moving average price is $8.56 and its two-hundred day moving average price is $7.62. The company has a market cap of $2.79 billion, a PE ratio of -13.28 and a beta of 1.17.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several large investors have recently made changes to their positions in AMRX. BNP Paribas Financial Markets grew its stake in shares of Amneal Pharmaceuticals by 62.2% in the 1st quarter. BNP Paribas Financial Markets now owns 99,192 shares of the company’s stock valued at $601,000 after buying an additional 38,031 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Amneal Pharmaceuticals by 18.8% in the 1st quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock worth $122,000 after purchasing an additional 3,177 shares during the last quarter. Swiss National Bank lifted its holdings in Amneal Pharmaceuticals by 13.8% in the 1st quarter. Swiss National Bank now owns 242,100 shares of the company’s stock worth $1,467,000 after purchasing an additional 29,400 shares during the last quarter. ProShare Advisors LLC lifted its holdings in Amneal Pharmaceuticals by 8.6% in the 1st quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock worth $133,000 after purchasing an additional 1,726 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Amneal Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock worth $83,193,000 after purchasing an additional 85,846 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.